Back to results
US 2026/0209773 A1Published application
COMPOSITIONS AND METHODS FOR TUNABLE REGULATION OF RNAi
AssigneeObsidian Therapeutics, Inc.
InventorsJan ter Meulen, Dhruv Sethi, Mara Christine Inniss
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods related to drug responsive domain (DRD)-regulatable RNA interference (RNAi). Such compositions and methods provide for inhibitory RNA molecule expression driven by regulated transcriptional activity.
Claims55
A set of nucleic acid sequences comprising:
- a first nucleic acid sequence that encodes a transcription factor activation domain;
- a second nucleic acid sequence that encodes a transcription factor DNA binding domain that binds to a specific nucleotide binding site;
- a third nucleic acid sequence that encodes a drug responsive domain (DRD);
- wherein at least one of the transcription factor activation domain, the transcription factor DNA binding domain, or the combination of the transcription factor activation domain and the transcription factor DNA binding domain is operably linked to the DRD;
- and
- a fourth nucleic acid sequence that encodes an inhibitory RNA molecule, the fourth nucleic acid sequence being operably linked to an inducible promoter comprising the specific nucleotide binding site;
- wherein the transcription factor activation domain and the transcription factor DNA binding domain interact to form a transcription factor capable of activating transcription of the inhibitory RNA molecule upon binding to the specific nucleotide binding site.
4 more elements
Dependencies are inferred from the claim text.